No profile data available.
Grace Therapeutics, Inc. (GRCE) is a healthcare company in the blood vessel treatment pharmaceuticals industry, based in Princeton, United States, with about 5 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$9.57 million. In Q1 2027 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $43.75 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage.
Grace Therapeutics reported $0 in revenue for fiscal year 2025. In Q1 2027 revenue was $0.
$43.75 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood vessel treatment pharmaceuticals) include DiaMedica Therapeutics Inc. (DMAC), Tenax Therapeutics, Inc. (TENX), Gossamer Bio, Inc. (GOSS), Cadrenal Therapeutics, Inc. (CVKD).